CI: Gastric vs. Small Bowel Feeding (2011)
Kortbeek JB, Haigh PI, Doig C. Duodenal vs. gastric feeding in ventilated blunt trauma patients: A randomized controlled trial. J Trauma. 1999; 46: 992-998.
PubMed ID: 10372614To evaluate transpyloric feeds as they have been proposed as a means of providing enteral nutrition more rapidly and minimizing morbidity in ventilated trauma patients.
- Injury severity score higher than 16
- Need ventilation more than 48 hours.
- Disruption of GI tract
- Traumatic pancreatitis
- Hemodynamic instability precluding transport to fluoroscopy for tube placement
- Hopeless prognosis
- Enrollment into another trial
- Prior nutrition support
- Failure to enroll patient within 72-hour admission to ICU.
Initial N
- N=89
- NG: N=43 (79% male)
- SB: N=37 (76% male).
Age
- NG: N=43; NS=34.7±15.7 years
- SB: N=37; NS=33.6±17.5 years.
Other Relevant Setting Characteristics
Trauma patients.
Anthropometrics
- ISS: NG=30.0±11 years vs. SB=33.0±9.7 years
- APACHE II: NG=18±6 vs. SB=18±7.4
Location
Canada.
Timing and Method of Measurements
- Baseline: Age, gender, ISS, APACHE II
- ICU stay: Time on ventilator (days).
Dependent Variables (Outcomes)
- Ventilator-associated pneumonia: Centers for Disease Control and Prevention criteria of new infiltrate of more than 48 hours duration confirmed by radiography plus at least two of the following:
- Temperature more than 38.5oC
- Leukocyte count higher than 3,000cm3
- Purulent sputum or isolation of pathogenic bacteria from endotracheal aspirate
- ICU LOS
- Days on mechanical ventilation
- Mortality
- Time to reach nutrition goal.
Independent Variables (Intervention or Procedure)
Gastric or SB placement of feeding tube.
- 43 gastric (G)
- 37 duodenal (D).
Key Findings
Transpyloric-duodenal feedings significantly reduced time to achieve nutrition goals, but did not decrease LOS or days on mechanical ventilation.
Outcomes of Gastric vs. Transpyloric Small Bowel Feeding
Outcome |
NG (N=43) |
Post-Pyloric (N=37) |
Statistical Significance |
Time to tolerate full-strength feedings for 24 consecutive hours | 43.8±22.6 hours | 34±7.1 hours | P=0.02 |
ICU LOS (mean, range) | 7 (3-32) | 10 (3-24) | P>0.05 |
Days on mechanical ventilation (median, range) | 25 (9-88) | 30 (16-47) | P>0.05 |
Ventilator-Associated Pneumonia | 18/43 (42%) | 10/37 (27%) | P>0.05 |
Mortality | 7% | 10.8% | P>0.05 |
Other Findings
Study was underpowered; 400 patients (200 per arm) would be required to demonstrate difference of pneumonia at 10% (α=0.05 at 90% power).
- Length of stay and ventilator days were not significantly different
- A larger trial is needed to determine 20% difference in pneumonia rates
- Transpyloric feeds significantly reduce the time to achieve targeted enteral nutrition.
Government: | Calgary Regional Health Authority |
University/Hospital: | University of Calgary (Canada) |
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | Yes | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | Yes | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | Yes | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | N/A | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | No | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |